Pharmacotherapy of scleritis: Current paradigms and future directions

Robert M. Beardsley, Eric B. Suhler, James T. Rosenbaum, Phoebe Lin

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

Introduction: Scleritis is an inflammatory condition affecting the eye wall that may be associated with a number of systemic inflammatory diseases. Because scleritis can be refractory to standard treatment, knowledge of the body of available and emerging therapies is paramount and is reviewed here. Areas covered: This review focuses on both traditional and emerging therapies for noninfectious scleritis. The authors cover the mechanisms of action and potential adverse effects of each of the treatment modalities. In addition, a summary of the significant MEDLINE indexed literature under the subject heading 'scleritis', 'treatment', 'immunomodulator' will be provided on each therapy, including commentary on appropriate use and relative contraindications. Novel treatments and potential drug candidates that are currently being evaluated in clinical trials with therapeutic potential will also be reviewed. Expert opinion: While oral nonsteroidal anti-inflammatory drugs and oral corticosteroids are widely used, effective, first-line agents for inflammatory scleritis, refractory cases require antimetabolites, T-cell inhibitors, or biologic response modifiers. In particular, there is emerging evidence for the use of targeted biologic response modifiers, and potentially, for local drug delivery.

Original languageEnglish (US)
Pages (from-to)411-424
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number4
DOIs
StatePublished - Mar 1 2013

Keywords

  • Alkylating agent
  • Antimetabolite
  • Biologic response modifier
  • Noninfectious
  • Scleritis
  • Therapy

Fingerprint Dive into the research topics of 'Pharmacotherapy of scleritis: Current paradigms and future directions'. Together they form a unique fingerprint.

Cite this